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ABSTRACT
Following emergence in late 2019, SARS-CoV-2 rapidly became pandemic and is presently responsible for millions of
infections and hundreds of thousands of deaths worldwide. There is currently no approved vaccine to halt the spread
of SARS-CoV-2 and only very few treatment options are available to manage COVID-19 patients. For development of
preclinical countermeasures, reliable and well-characterized small animal disease models will be of paramount
importance. Here we show that intranasal inoculation of SARS-CoV-2 into Syrian hamsters consistently caused
moderate broncho-interstitial pneumonia, with high viral lung loads and extensive virus shedding, but animals only
displayed transient mild disease. We determined the infectious dose 50 to be only five infectious particles, making
the Syrian hamster a highly susceptible model for SARS-CoV-2 infection. Neither hamster age nor sex had any impact
on the severity of disease or course of infection. Finally, prolonged viral persistence in interleukin 2 receptor gamma
chain knockout hamsters revealed susceptibility of SARS-CoV-2 to adaptive immune control. In conclusion, the Syrian
hamster is highly susceptible to SARS-CoV-2 making it a very suitable infection model for COVID-19 countermeasure
development.
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Introduction
Since emergence of SARS-CoV-2 in late 2019, the virus
has spread across the globe causing >56 million
confirmed infections resulting in over 1,300,000 deaths
[1]. SARS-CoV-2 causes coronavirus disease
(COVID)-19, which is associated with a broad range of
symptoms. These symptoms are most commonly fever,
dry cough and fatigue, but can also include myalgia,
headache, loss of taste or smell, sore throat, congestion,
runny nose, nausea and diarrohea. The incubation
period of SARS-CoV-2 ranges from 2–14 days with 5–
6 days being most common [2]. While the majority of
infections are asymptomatic or present as mild to mod-
erate cases, a small percentage of patients will progress
into acute respiratory disease with fatal outcome [3,4].
In the absence of a licensed vaccine and only limited
treatment options available, scientific and health care
communities continue their efforts to rapidly find effec-
tive countermeasures for SARS-CoV-2 infections. Aside
fromnewdrugor vaccinedevelopment, repurposing and
“off-label” use of existing FDA-approved compounds is
being heavily pursued, often omitting preclinical animal
studies before moving directly into humans [5–8].
Preclinical animal models are integral to evaluating
countermeasures for infectious diseases such as
COVID-19. Non-human primate (NHP) COVID-19
models have been established, and several Old-World
monkey species have been shown to be susceptible to
SARS-CoV-2 infection. Infection in these animals
results in a transientmild tomoderate interstitial pneu-
monia, rather than the severe clinical outcomes [9–11].
Ferrets have also been shown to be susceptible to SARS-
CoV-2 infection resulting in mild disease with shed-
ding from the upper respiratory tract. Efficient trans-
mission has been documented suggesting the ferret
may be a valuable preclinical model for transmission
but not for severe disease [12–14].
Development of small animal SARS-CoV-2 infec-
tion models was initially delayed, but recently both
mouse and hamsters COVID-19 models have been
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described [15–19]. The mouse angiotensin-convert-
ing enzyme 2 (ACE-2) receptor has only low affinity
for the SARS-CoV-2 spike protein leading to poor
binding and entry [20,21]. Initially, mouse suscepti-
bility to SARS-CoV-2 infection was increased
through transduction of the respiratory tract cells
using adenovirus vectors expressing human ACE2,
which lead to development of non-lethal pneumonia
[22,23]. Several receptor transgenic mice have since
been created, expressing human ACE2 under tissue-
specific promoters or the endogenous mouse ACE2
promoter [16, 24–26]. All of these mice are suscep-
tible to SARS-CoV-2 infection, resulting in a range
of clinical signs with mild to fatal disease depending
on the transgene. SARS-CoV-2 adaptation to mice
has also been attempted through either serial passa-
ging or reverse genetics. So far this approach has sen-
sitized multiple strains of mice to infection in the
upper and lower respiratory tracts, leading to very
mild disease [15,27].
Syrian hamsters have been reported to be suscep-
tible to SARS-CoV-2 infection developing moderate
interstitial pneumonia leading to transient mild to
moderate disease [17,19]. However, these studies
have used varying doses of SARS-CoV-2 for inocu-
lation, and the impact of age and sex on infection
and disease is unclear. Herein, we defined the Syrian
hamster as a SARS-CoV-2 infection and disease
model and refined further virologic and host par-
ameters to increase the value of this small animal
model. First, we demonstrated high functional inter-
action of the SARS-CoV-2 receptor binding domain
(RBD) with the hamster ACE2 receptor. Next, we
determined the SARS-CoV-2 dose causing infection
in 50% of animals (ID50) following intranasal infec-
tion, showing these animals to be highly susceptible
to infection. We detailed the progression of SARS-
CoV-2 infection, and also the effect of sex and age
on SARS-CoV-2 infection in the model. Finally, we
investigated SARS-CoV-2 infection of interleukin 2
receptor, gamma chain (IL2RG) knockout hamsters
to assess the impact of adaptive (and NK) immunity
in this model.
Materials and methods
Biosafety and ethics. All work using live SARS-COV-
2 was performed in BSL4 using standard operating
protocols approved by the Rocky Mountain Labora-
tories Institutional Biosafety Committee. All animal
work was approved by the Institutional animal Care
and use Committee and performed in strict accord-
ance with the recommendations described in the
Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health, the Office of Ani-
malWelfare, the United States Department of Agricul-
ture in an association for Assessment and
Accreditation of Laboratory Animal Care-Accredited
Facility. Animals were group housed in HEPA-filtered
cage systems enriched with nesting material. Com-
mercial food and water were available ad libitum.
Virus. SARS-CoV-2 isolate nCoV-WA1-2020
(MN985325.1) was kindly provided by CDC as Vero
passage 3 [28]. The virus was propagated once in
Vero E6 cells in DMEM (Sigma) supplemented with
2% foetal bovine serum (Gibco), 1 mM L-glutamine
(Gibco), 50 U/ml penicillin and 50 μg/ml streptomy-
cin (Gibco) (virus isolation medium). Whole genome
sequencing of virus stock revealed it was 100% identi-
cal to the initial deposited Genbank sequence
(MN985325.1) and no contaminants were detected.
Cells. Vero E6 cells were maintained in DMEM
(Sigma) supplemented with 10% foetal calf serum
(Gibco), 1 mM L-glutamine (Gibco), 50 U/ml penicil-
lin and 50 μg/ml streptomycin (Gibco). 293T and baby
hamster kidney (BHK) were maintained in DMEM
(Gibco) supplemented with foetal bovine serum, peni-
cillin/streptomycin and L-glutamine.
Plasmids. SARS-CoV-2 spike protein plasmids
were previously described [20]. Sequences from
SARS-CoV-1/Urbani spike (GenBank MN908947),
SARS-CoV-2 spike RBD (AY278741), human ACE2
(GenBank Q9BYF1.2) and hamster ACE2 (GenBank:
XP_005074266.1) were codon optimized for humans
and cloned into pcDNA3.1 + .
Cell entry assay. Vesicular stomatitis virus (VSV)
particles were pseudotyped with different wildtype or
chimeric spike proteins or no spike in 293T cells as
previously described [20]. BHK cells were transfected
in 96-well format with 100 ng of host receptor plas-
mid, or no receptor and subsequently infected with
spike-pseudotyped VSV particles as previously
described [20]. Approximately 18 h later, luciferase
was measured using the BrightGlo reagent (Promega),
following the manufacturer’s instructions.
Animal studies. Syrian hamsters (Mesocricetus
auratus), 6-8-weeks-of-age and >27-weeks-of-age,
males and females, were purchased from Envigo.
IL2RG KO hamsters were generated with CRISPR/
Cas9-mediated gene targeting technique established
in the hamster by Utah State University as reported
previously [29]. Hamsters were anesthetized by inha-
lation of vaporized isoflurane and inoculated via intra-
nasal instillation with 50 µl of varying concentrations
of inoculum (1–1 × 105 tissue culture dose 50
(TCID50)) dropped into each naris (25ul/naris) using
a pipette. Hamsters were weighed and monitored
daily for signs of disease. Temperature transponders
(BMDS IPTT-300) were implanted subcutaneously
under anesthesia just above the shoulder blades in a
subset of hamsters to monitor and record tempera-
tures daily. Swabs (oral and rectal) were taken at
different days post-infection using polyester flock
tipped swabs (Puritan Medical Products). Animals
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were euthanized for necropsies at different timepoints
to assess disease.
Virus titration. Virus was quantified through end-
point titrations performed in Vero E6 cells. Tissue was
homogenized in 1ml DMEM using a TissueLyzer
(Qiagen) and centrifuged to remove cellular debris
(10 min at 8,000 rpm). Cells were inoculated with
10-fold serial dilutions of clarified tissue homogenate
or whole blood samples in 100 µl DMEM (Sigma-
Aldrich) supplemented with 2% foetal bovine serum,
1 mM L-glutamine, 50 U/ml penicillin and 50 µg/ml
streptomycin. Cells were incubated for seven days
and then scored for cytopathic effect (CPE). The
TCID50 was calculated via the Reed-Muench formula
[30].
Viral genome load. qRT-PCR was performed on
RNA extracted from blood and swabs using QiaAmp
Viral RNA kit (Qiagen) according to the manufac-
turer’s instructions. Tissues (≤ 30 mg) were homogen-
ized in RLT buffer and RNA was extracted using the
RNeasy kit (Qiagen) according to the manufacturer
protocol. Viral genomic RNA (gRNA) was detected
with a one-step real-time RT–PCR assay (Quantifast,
Qiagen) using primers and probes generated to target
either the SARS-CoV-2 E [31] or N gene (forward: 5’-
AGAATGGAGAACGCAGTGGG; reverse: 5’- TGA-
GAGCGGTGAACCAAGAC; probe: 5’-CGAT-
CAAAACAACGTCGGCC synthesized with 5’ 6-
carboxyfluorescein, internal Zen quencher and 3’
Iowa black quencher); all primers and probes were
synthesized by Integrated DNA Technologies (IDT).
Dilutions of RNA standards quantified by droplet
digital PCR were run in parallel and used to calculate
gRNA copies with the E assay. The N-based assay used
a standard curve synthesized as follows: T7 in vitro
transcription (ThermoFisher) of a synthetically pro-
duced N sequence (IDT) was used to generate tem-
plate RNA. RNA was quantified by 260nm
absorbance to determine copy number and a standard
curve generated by serial dilution.
Histopathology and immunohistochemistry.
Tissues were fixed in 10% neutral buffered formalin
(with two changes) for a minimum of 7 days. Tis-
sues were placed in cassettes and processed with a
Sakura VIP-6 Tissue Tek on a 12-hour automated
schedule, using a graded series of ethanol, xylene,
and ParaPlast Extra. Embedded tissues are sec-
tioned at 5um and dried overnight at 42°C prior
to staining. Specific anti-CoV immunoreactivity
was detected using GenScript U864YFA140-4/
CB2093 NP-1 at a 1:1,000 dilution. The secondary
antibody is an anti-rabbit IgG polymer from Vector
Laboratories ImPress VR. Tissues were then pro-
cessed for immunohistochemistry using the Discov-
ery Ultra automated processor (Ventana Medical
Systems) with a ChromoMap DAB kit (Roche Tis-
sue Diagnostics).
Statistical analyses. Statistical analysis was per-
formed in Prism 8 (GraphPad). T-tests were used to
assess studies with 2 groups, ANOVA was used to ana-
lyse studies with >2 groups.
Results
The SARS-CoV-2 spike protein binds to the Syrian
hamster ACE2 receptor. To validate that that SARS-
CoV-2 can bind and then use as an entry receptor
the Syrian hamster ACE2 receptor, a VSV pseudotype
assay was performed as previously published [20].
Briefly, a chimeric SARS-CoV-1 spike protein was
generated with the RBD replaced with the SARS-
CoV-2 RBD (VSV-SARS-CoV-2-RBD), a psuedotype
that has previously shown comparable binding to
ACE-2 as the WT [20,32]. We transfected BHK cells
that do not express ACE2 with expression plasmids
for either human or hamster ACE2, or empty vector
as a negative control. Cells were then infected with
the VSV pseudotyped particles carrying either SARS-
CoV-1 full-length spike (VSV-SARS-CoV-1-RBD) or
chimeric VSV-SARS-CoV-2-RBD. As anticipated,
both VSV-SARS-COV-1-RBD and VSV-SARS-CoV-
2-RBD were unable to enter BKH cells, but entry
was rescued in transduced cells expressing the hamster
or human ACE2. Interestingly, VSV-SARS-CoV-2-
RBD entry was increased compared to VSV-SARS-
CoV-1-RBD, independent of the ACE2 origin, which
may indicate higher susceptibility of both hamsters
and humans to SARS-CoV-2 compared to SARS-
CoV-1 (Figure 1).
Syrian hamsters are highly susceptible to SARS-
CoV-2. To determine the level of susceptibility of
Figure 1. SARS-CoV-2 spike receptor binding data. A VSV
pseudotype assay was used to assess the binding affinity of
the SARS-CoV-2 RBD. BHK cells expressing either the human
or Syrian hamster or no ACE2 receptor were infected with
VSV-pseudotyped particles carrying either the SARS-CoV-1
spike (S) protein or a chimeric SARS-CoV-1 spike with the
SARS-CoV-2 receptor binding domain (RBD). Note: red circles,
SARS-CoV-1 S; yellow circles with red outline, SARS-CoV-1 S
with SARS-CoV-2 RBD; black circle, no ACE-2; S, spike protein;
RBD, receptor binding domain.
Emerging Microbes & Infections 2675
Syrian hamsters to SARS-CoV-2 infection, four
groups of six hamsters aged 4–6 weeks were infected
with limiting dilutions of SARS-CoV-2 to determine
the ID50. Groups were intranasally infected with a
ten-fold serial dilution series of virus ranging from
103 to 100 TCID50, and infection course was moni-
tored by signs of disease including weight and temp-
erature. Although no significant changes in
temperature over the experimental period were
observed, weight loss between the animal groups
directly correlated with the infectious dose (Figure 2
(A)). Oral and rectal swabs were taken at 3 days post
infection (dpi) and 5dpi to measure differences in
levels of viral gRNA between the different groups.
Only one animal in the group receiving the 1
TCID50 dose had detectable gRNA in the oral swabs
and none in the rectal swab (Figure 2(B)), with only
half the animals in this group being positive at 5dpi
(Figure 2(C)). Lungs were harvested at 5dpi and
gRNA and infectious titres were determined. Remark-
ably similar gRNA levels were found across groups
infected with 10 TCID50 or higher, only the 1
TCID50 group had a significant reduction in gRNA
levels (Figure 2(D)). Infectious titres from the lungs
of each dose group had a similar pattern with high
viral loads in all groups, except the 1 TCID50 group
for which no infectious virus was detected (Figure 2
(E)). Remarkably, this series of experiments shows
the ID50 in Syrian hamsters to be only 5 TCID50
when administered intranasally.
SARS-CoV-2 infection of Syrian hamsters results
in broncho-interstitial pneumonia. To characterize
the extent of disease in this model, two groups of 10
Syrian hamsters aged 4–6 weeks were intranasally
infected with either 500 ID50 (low dose; 10
3 TCID50)
or 5 × 104 ID50 (high dose; 10
5 TCID50) of SARS-
CoV-2. Animals were monitored for clinical symp-
toms of disease with the intent of euthanizing a subset
of animals for analysis when early symptoms became
apparent. At 3dpi hamsters in both groups had lost
weight on consecutive days (Figure 3(A)) and dis-
played slightly ruffled fur with minor changes in res-
piration pattern. Four animals from each group were
euthanized at this time (3dpi) for analysis. Lungs
were examined for gross pathology and all animals
had lung lesions consisting of focal extensive areas
of pulmonary edema and consolidation with evidence
of interstitial pneumonia characterized by a failure of
the lungs to collapse following removal. No gross
pathology was observed in other tissues collected
including liver, spleen, kidney and brain. The remain-
ing hamsters continued to lose weight until 5dpi with
a maximum loss of <10% body weight (Figure 3(A));
clinical signs remained similar until 5dpi. Three
more animals from each group were euthanized at
this time (5dpi). At necropsy, an increase in both
number and severity of lesions were observed in
animals receiving the low dose, but gross pathology
was similar in appearance at 3dpi and 5dpi in animals
receiving the high dose. Following four consecutive
days of weight gain (Figure 3(A)) and improving clini-
cal signs, the remaining animals from each group were
euthanized at 10dpi. Gross examination of the lungs at
10dpi showed a significant reduction in both lesion
severity and congestion relative to lungs taken earlier
during disease progression. Despite the obvious devel-
opment of respiratory disease at earlier times post-
infection, clinical signs were minimal at this stage
(10dpi) with animals having recovered weight (Figure
3(A)). Oral and rectal swabs were collected at each
time point to monitor viral gRNA shedding. Shedding
peaked in all swab types at 3dpi with a small decrease
at 5dpi before dropping significantly at 10dpi (Figure 3
(B,C)). Lungs were evaluated for both SARS-CoV-2
gRNA and infectious titres. gRNA loads in the lungs
were high with >1010 genome copies/gram (Figure 3
(D)), whereas gRNA loads in other organs were
approximately 4–5 logs lower (Sup. Figure 1). Lung
infectious titres were 107 TCID50 per gram at 3dpi
although this had already decreased at 5dpi and was
absent in all but one animal at 10dpi (Figure 3(E)).
Overall, there was no significant difference between
the groups infected with the low and high dose of
SARS-CoV-2, except for 10dpi where one animal
remained positive.
ACE2 immunoreactivity is observed in the convo-
luted tubules of the kidney and liver sinusoids but is
not routinely detected in the trachea or lung [33].
Interestingly, no significant histopathologic lesions
were observed in the evaluated sections of liver, kid-
ney and spleen of any animal regardless of age, sex or
inoculation dose used in these studies. Immunohisto-
chemistry also failed to reveal SARS-CoV-2 antigen
in the liver, kidney and spleens examined. Pathologi-
cally, changes associated with disease in the lower res-
piratory tract were noted in both the trachea and lung
regardless of the inoculation dose. The observed
pathology had a more distinct progression in the
low (500 ID50) inoculation dose than the higher
dosed group (5 × 104 ID50). Evidence of broncho-
interstitial pneumonia was observed at all evaluated
time points. At 3dpi, lesions were characterized by
epithelial necrosis in the trachea and bronchioles,
squamous metaplasia of the mucosa in the trachea,
bronchiolitis characterized by influx of neutrophils
and macrophages into the lamina propria and mild
interstitial pneumonia with expansion of alveolar
septa by edema fluid, with few strands of fibrin and
low numbers of leukocytes (Figure 4(A-C)). By
5dpi, the interstitial pneumonia was moderate to
severe with fibrin leaking into alveolar spaces, alveo-
lar edema, influx of moderate numbers to numerous
neutrophils and macrophages into alveolar spaces,
presence of syncytial cells in bronchioles and alveolar
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spaces and prominent type II pneumocyte hyperpla-
sia (Figure 4(D-F)). Evidence of lesion resolution
was observed at 10dpi with a decrease in alveolar cel-
lular exudate, absence of epithelial necrosis and a pro-
minent “honeycombing” pattern of type II
pneumocyte hyperplasia centred on terminal bronch-
ioles with septal expansion by a small to moderate
amount of fibrosis (Figure 4(G-I)) as compared to
naïve infected control animals (Figure 4(J-L)). Mild
and multifocal pleural fibrosis was observed at
10dpi (Figure 5). At both 5dpi and 10dpi, moderate
numbers of blood vessels were surrounded by peri-
vascular infiltrates of lymphocytes that frequently
formed distinct perivascular cuffs, occasionally
focally disrupting the tunica media or forming aggre-
gates between the tunica intima and media elevating
the endothelium into the lumen. Immunohistochem-
ical reaction demonstrated viral antigen in bronchiole
epithelial cells at 3dpi (Figure 5(A-C)) with fewer
cells showing immunoreactivity at 5dpi (Figure 5
(D-E)) and no epithelial cells exhibiting immunor-
eactivity at 10dpi (Figure 5(G-I)). Lower in the respir-
atory tree, SARS-CoV-2 immunoreactivity was
demonstrated in type I and II pneumocytes as well
as alveolar macrophages at 3dpi and 5dpi with a
lack of immunoreactivity at 10dpi (Figure 5(G-I))
which is comparable to uninfected control tissue
(Figure 5(J-L)) Overall, pathologic changes pro-
gressed more rapidly in animals infected with the
high dose relative to the low dose, but severity of dis-
ease was consistent between the groups with all ani-
mals developing moderate to severe broncho-
interstitial pneumonia, commensurate with a mild
to moderate infection model.
Neither age nor gender affected disease severity
or outcome. To determine whether age or gender
would affect disease progression following SARS-
CoV-2 infection, we infected both young (4-6 weeks
Figure 2. Susceptibility of Syrian hamsters to SARS-CoV-2. Syrian hamsters were inoculated intranasally with 10-fold limiting
dilutions of SARS-CoV-2 beginning at 103 TCID50. Weights were collected daily and shedding was assessed via swab samples (nasal
and rectal) collected at 3 and 5 dpi. Viral loads were determined as genome copies and infectious virus. (A) Daily weights. (B)
Shedding at 3 dpi. (C) Shedding at 5 dpi. (D) Viral genome load in the lungs at 5 dpi. (E) Infectious lung titres at 5 dpi. A statistical
significance was found between the groups presented in (A), with the group receiving the highest dose of 103 TCID50 losing the
most weight. The group receiving the second highest infectious dose (102 TCID50) lost statistically less than the 10
3 TCID50 group
but statistically more weight than the 2 groups receiving the two lowest infectious doses. (B-E) A statistically significance differ-
ence was found between the group receiving the lowest dose (100 TCID50) and all other groups. Multiple t tests comparing groups
directly were used to analyse significance. Note: blue circles, 100 TCID50 dose; red square, 10
1 TCID50 dose; green triangle, 10
2
TCID50 dose; purple triangle, 10
3 TCID50 dose.
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old) and aged (>27 weeks old) male and female ham-
sters with the low dose of 500 ID50 (10
3 TCID50) by the
intranasal route. Consistent with previous studies, ani-
mals began to show mild clinical signs of disease and
weight loss peaking at 5dpi or 6dpi (Figure 6(A)). A
subset of animals in each age group and gender were
euthanized for analysis at 3, 5 and 11dpi. Lung pathol-
ogy was comparable in all groups at each time point
throughout the study. Gross lung lesions were evident
at 3dpi, had worsened by 5dpi before mostly resolving
at 11dpi (Supp. Figure 2A). To help determine disease
severity, lung weights were recorded and calculated as
a percentage of overall body weight for comparison.
Lungs weights paralleled the observed lesions and
were significantly increased at 5dpi (Supp. Figure
2B). These observations were consistent with the
development of pneumonia and were independent of
sex and age.
High levels of viral gRNA were detected in oral and
rectal swabs in all groups. The highest gRNA levels
detected were 3dpi before decreasing at 5dpi and
again at 11dpi where only a subset remained positive
(Figure 6(B,C)). Interestingly, all oral swabs were posi-
tive at 11dpi suggesting viral replication was still
ongoing in the upper respiratory areas (Figure 6(B)).
Several tissues including blood were collected and
examined by qRT-PCR for viral gRNA loads at each
timepoint. The lungs had high viral loads with
gRNA levels highest 3dpi before decreasing at 5dpi
and again at 11dpi (Figure 6(D)). This corresponded
with infectious titres which followed a similar pattern
and peaked at 3dpi (Figure 6(E)). The brain consist-
ently had the second highest levels of viral gRNA
detected and remained relatively stable across the
groups at >108 TCID50 equivalents at the time points
examined. The digestive tract, both upper and lower,
exhibited levels of gRNA of >106 TCID50 equivalents
across the study. Liver, spleen and kidneys all had
similar levels of gRNA at 3dpi and 5dpi with >104
TCID50 equivalents before decreasing at 11dpi.
Hamsters lacking interleukin-2 receptor subunit
gamma (IL2RG KO) show persistent infection with
SARS-CoV-2. IL2RG KO hamsters are unable to
develop mature NK cells with compromised
Figure 3. Increased infectious dose does not affect shedding or disease severity. Syrian hamsters were infected intranasally
with either 500 ID50 (10
3 TCID50) or 5 × 10
4 ID50 (10
5 TCID50) of SARS-CoV-2. Samples were collected at the time points noted.
Weight were collected daily, shedding from mucosal membranes and viral genome load and infectivity in the lungs were
measured. (A) Daily weights. (B) Viral genome load recovered from nasal swabs. (C) Viral genome load recovered from rectal
swabs. (D) Viral genome load in the lungs. (E) Infectious titres in the lungs. T-tests were used to compare the two groups at
each time where samples were collected. A significant difference was observed at 10 dpi in the lung titres (E), but no other sig-
nificant differences were observed in this study. Note: blue circles, 105 TCID50 dose; red square, 10
3 TCID50 dose.
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development of T and B lymphocytes [29,34]. This
lack of mature lymphoid cells results in an immuno-
compromised status known as X-linked severe com-
bined immunodeficiency (XSCID) in humans [35].
To ask the question of whether these key cellular
aspects of the innate (NK) and adaptive (B and T
cells) impact SARS-CoV-2 replication and associated
disease, we assessed infection in IL2RG KO hamsters.
Similar to immunocompetent Syrian hamsters, follow-
ing infection with 5 × 104 ID50 (high dose; 10
5
TCID50) of SARS-CoV-2, four (2 males, 2 females)
IL2RG KO hamsters lost approximately 5-10% of
their body weight over the first 5 days following infec-
tion before recovering (Figure 7(A)). Oral and rectal
swabs were taken at 5dpi and 24dpi to measure shed-
ding. Interestingly, both oral and rectal swabs were
positive at both time-points and at very similar levels
(Figure 7(B)). All four hamsters were euthanized
24dpi following 2 weeks of consistent weight gain
and lungs were examined for disease. At examination,
the lungs had lesions similar to the immunocompetent
hamsters at 5dpi, were congested and failed to col-
lapse. Remarkably, virus titration performed on lung
tissue revealed high infectious titres ranging from
Figure 4. SARS-CoV-2 infection of Syrian hamsters results in broncho-interstitial pneumonia. Syrian hamsters were infected
intranasally with 500 ID50 (10
3 TCID50) of SARS-CoV-2. Lungs were fixed in 10% formalin, cut and stained with Hematoxylin and
Eosin (HE) to examine pulmonary pathology at 3, 5 and 10 dpi. (A-C), 3 dpi. (A) Inflammation initiates within interstitial spaces in
and around terminal airways with a minimal cellular exudate into the airway spaces (100x, size bar is 50um). (B) Bronchiolar epi-
thelial necrosis with influx of neutrophils into the mucosa and airway lumen (400x, size bar is 20um). (C) Attenuation of the tra-
cheal mucosa with loss of apical cilia accompanied with an influx of moderate numbers of degenerate and non-degenerate
neutrophils (400x, size bar is 20um). (D-F), 5 dpi. (D) Locally extensive inflammation is noted (100x, size bar is 50um). (E) Progress-
ive bronchiolitis with degenerate and non-degenerate neutrophils and exudate within the lumen and prominent epithelial syn-
cytial cells (arrows; 400x, size bar is 20um). (F) Alveolar spaces contain macrophages and neutrophils. Alveolar septa are thickened
and expanded by fibrin, edema fluid and infiltrating leukocytes and are lined by prominent type II pneumocytes (arrowhead) and
rare syncytial cells (arrow; 400x, size bar is 20um). (G-I), 10 dpi. (G) Resolving inflammation is largely limited to bronchioles and the
adjacent alveolar spaces (100x, size bar is 50um) (H) Alveolar septa are thickened by collagen with lymphocytes and lined by
numerous plump type II pneumocytes that surround low numbers of foamy alveolar macrophages (400x, size bar is 20um). (I)
Multifocal pleural fibrosis is evident with mild subpleural inflammation (200x, size bar is 20um). (J-L), naïve animals. (J) Normal
interstitial spaces (100x, size bar is 50um). (K) Normal bronchiolar epithelium (400x, size bar is 20um). (L) Normal tracheal mucosa
(400x, size bar is 20um).
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107 - 109 TCID50 per gram of tissue, even at 24dpi
(Figure 7(C)).
Histopathologic analysis of the lung sections of all
evaluated IL2RG KO hamsters exhibited dissemi-
nated, moderate to severe, chronic-active interstitial
pneumonia. Alveolar septa were expanded by moder-
ate amounts of fibrin, variably well-organized bun-
dles of collagen and infiltrated by moderate
numbers of neutrophils and macrophages. Adjacent
alveolar spaces frequently contained moderate num-
bers to numerous macrophages with fewer degenerate
and non-degenerate neutrophils admixed with cellu-
lar debris (Figure 7(D)). Greater than 50% of evalu-
ated alveolar spaces were lined by type II
pneumocytes that occasionally exhibited pseudo-stra-
tified, columnar epithelial differentiation with a dis-
tinct ciliated apical border. Lymphocyte infiltrates
and perivascular lymphoid aggregates were absent
in all evaluated sections. Immunohistochemical reac-
tion revealed numerous immunoreactive type I and
type II pneumocytes as well as immunoreactive
ciliated bronchiolar epithelial cells (Figure 7(E)). His-
topathologic evaluation of the spleen confirmed the
absence of lymphoid follicles and peri-arteriolar lym-
phoid sheaths. Extramedullary hematopoiesis, noted
in both the spleen and liver, consisted entirely of ery-
throid lineage cell populations.
Discussion
SARS-CoV-2 infection in humans varies from asymp-
tomatic to severe respiratory disease that can be fatal,
especially in elderly and otherwise immunocompro-
mised individuals. The lack of preclinical animal
Figure 5. SARS-CoV-2 viral antigen in the lungs over the course of infection. Syrian hamsters were infected intranasally with
500 ID50 (10
3 TCID50) of SARS-CoV-2. Histopathology (HE) and immunohistochemistry (IHC) was used to assess pathology with the
presence of SARS-CoV-2 antigen in pulmonary sections at 3, 5 and 10 dpi. (A-C), 3 dpi. (A) Histopathology is largely limited to
bronchioles and terminal airway spaces and is not readily apparent at a low magnification (H&E, 20x, size bar is 200um). (B) Immu-
nohistochemical reaction highlights antigen distribution in bronchioles and terminal airway spaces (20x, size bar is 200um). (C)
Bronchiolar epithelial cell immunoreactivity with limited antigen detection in alveolar spaces (100x, size bar is 50um). (D-F), 5 dpi.
(D) Extension of cellular exudate from bronchioles into alveolar spaces (H&E, 20x, size bar is 200um). (E) Immunoreactivity is
detected along the periphery of regions of pathology and has largely been cleared from bronchiolar epithelium (20x, size bar
is 200um). (F) Immunoreactivity is noted in type I and type II pneumocytes and few alveolar macrophages (200x, size bar is
20um). (G-I), 10 dpi (G) Resolving inflammation is limited to bronchioles and adjacent terminal airways (H&E, 20x, size bar is
200um). (H) SARS-CoV-2 immunoreactivity is not observed in regions of resolving inflammation (20x, size bar is 200um). (I) No
immunoreactivity is observed (200x, size bar is 20um). (J-L), naïve animals. (J) Normal interstitial spaces (100x, size bar is
50um). (K) Normal bronchiolar epithelium (400x, size bar is 20um). (L) Normal tracheal mucosa (400x, size bar is 20um).
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models that replicate the severe disease of some
COVID-19 patients is a substantial hurdle for the pro-
gression of promising countermeasures from in vitro
testing through to clinical trials. A reliable small ani-
mal model would allow reproducible, in-depth ana-
lyses of infection patterns, elucidation of the
immune response to SARS-CoV-2 infection and
serve as a critical preclinical model for the initial in
vivo step in evaluating COVID-19 countermeasures
for human use.
The Syrian hamster has been established as a
SARS-CoV-2 animal model, but a more thorough
analysis had yet to be performed. To expand our
understanding the Syrian hamster model, we first
determined that the hamster ACE2 receptor was
compatible with the SARS-CoV-2 spike protein
binding domain. The level of binding and entry
was consistently higher than the corresponding
assay testing human ACE2 binding activity. As the
receptor binding data suggested and other recent
studies have shown, Syrian hamsters were susceptible
to SARS-CoV-2 infection resulting in moderate to
severe broncho-interstitial pneumonia and prolonged
virus shedding of at least 10 days. The ID50 of SARS-
CoV-2 in the Syrian hamster is low, roughly five
infectious particles will result in a productive infec-
tion in 50% of animals.
Symptoms of disease appear approximately 3dpi,
but clinical signs are minimal with a consistent but
not severe weight loss of 5-10%. Ruffled fur may be
observed in some hamsters, respiration rates may
increase slightly, but the behaviour is unchanged
from naïve hamsters. Infection was systemic follow-
ing intranasal inoculation and viral gRNA was
detected in all tissues examined. However, the lungs
were the major site of viral replication and clearly
Figure 6. Neither age nor sex affects shedding or disease following infection with SARS-CoV-2. To compare the effects of
aging and sex on disease following SARS-CoV-2 infection, young female and male (4-6weeks) and aged female and male
(>6months) Syrian hamsters were infected intranasally with 500 ID50 (10
3 TCID50) of SARS-CoV-2. Samples were collected at
the time points noted. Weights were collected daily, shedding and viral loads in the lungs were measured. (A) Daily weights.
(B) Viral genome load recovered from oral swabs at each time point. (C) Viral genome load recovered from rectal swabs at
each time point. (D) Viral genome load recovered from lungs at each terminal point. (E) Infectious titres in the lungs. ANOVA
was used to compare groups at each time where samples were collected. No significant differences were observed between
groups at any time point collected in in this study. Note: blue circles, aged females; red circle, aged male; green circle, young
female; purple circle, young male.
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showed a consistent but moderate pathology. Follow-
ing intranasal infection, interstitial pneumonia initi-
ating as bronchiolitis and focusing around terminal
airways developed at 3dpi but was more severe in
the animals receiving higher infectious doses at this
early time point. Pulmonary pathology continued to
increase in severity and extent of lesions in the
lower dosed animals and was more severe at 5dpi,
with characteristic evidence of coronaviral infection
noted including presence of syncytial cells in bronch-
ioles and alveolar spaces. Pulmonary pathology was
diminished by 10dpi in all animals examined at
those times with characteristic evidence of epithelial
regeneration noted.
In the human population, there have been reports
of an increase in COVID-19 severity in males
[36,37] as well as a disparity of COVID-19 severity
among different age groups [38,39]. In these studies,
neither age nor gender was a factor in disease severity
or outcome. Young hamsters had similar shedding
kinetics, virus titres in the lungs and developed similar
pulmonary pathology as aged hamsters regardless of
sex. Importantly, all animals taken at the late time-
points showed evidence of recovery from disease at a
similar rate.
Interestingly, elimination of host adaptive immune
responses in the IL2RG KO model resulted in a
chronic infection persisting at least 24 days. Virus
was detectable in oral and rectal swabs at 5dpi and
at study termination (24dpi). Histopathology evalu-
ated at 24dpi supports a chronic-active infection of
the respiratory system with foci of epithelial regener-
ation as well as active recruitment of neutrophils and
macrophages. Unlike the immunocompetent hamster
model, in which antigen was only detectable outside
of regions of pathology, SARS-CoV-2 antigen was
detectable in type I and type II pneumocytes, hyper-
plastic pneumocytes in regions of regeneration and
macrophages. Additionally, viral antigen was present
in morphologically normal bronchial epithelial cells
at 24dpi, a feature only routinely observed at 3dpi in
the immunocompetent hamster model. While histo-
pathology revealed a moderate to severe pulmonary
inflammatory response, clinical signs of severe respir-
atory disease was not observed in this model. These
data suggest that the innate immune system, in the
background of compromised adaptive immunity, is
capable of depressing the viral infection enough to
keep respiratory physiology relatively stable, but
incapable of eliminating SARS-CoV-2 infection.
Additionally, vascular changes and perivascular leuko-
cyte infiltrates were not observed in the IL2RG KO
model, unlike the immunocompetent hamster
model. This data, even though limited to four animals,
suggests that the adaptive immune response or IL-2
signalling pathway may play a critical role in the
Figure 7. SARS-CoV-2 infection of Interleukin-2 receptor subunit gamma knockout hamsters (IL2RG-/-) results in persistent infec-
tion and pneumonia. IL2RG KO hamsters lacking mature B-cells, T-cells and NK cells, were infected with 5 × 104 ID50 (10^5 TCID50)
and followed for 24 days to determine if disease developed. Weights were collected daily and shedding from mucosal membranes
and viral infectivity in the lungs were measured at the time points noted. (A) Daily weights. (B) Viral genome load recovered from
oral and rectal swabs at each time point. (C) Infectious titres in the lungs. (D) Alveoli frequently contain macrophages, neutrophils
and sloughed epithelial cells, and are lined by numerous hyperplastic type II pneumocytes (H&E, 200x). (E) Immunoreactivity is
observed in hyperplastic type II pneumocytes and macrophages (Anti-SARS-CoV-2 nuclear protein, 200x). Note (B): blue circles, oral
swabs; red circle, rectal swabs. Size bar is 100um.
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development of innate leukocyte recruitment and sta-
ging during viral infection and the regulation of the
coagulation cascade in response to a pro-inflamma-
tory local environment.
Both autopsy and terminal biopsy samples from
human patients exhibiting COVID-19 disease have
shown histologic evidence of diffuse alveolar disease,
and death is frequently attributed to the clinical pro-
gression of pneumonia, often times resulting in
acute respiratory distress. Diffuse alveolar disease in
SARS-CoV-2 infection has characteristic lesions of
hyaline membrane formation in alveolar spaces
accompanied with proteinaceous fluid leaking from
damaged vessels into alveolar spaces. In hamsters,
there is evidence of alveolar epithelial damage at
peak virus replication with lesion resolution later on.
However, the hamster model fails to develop fulmi-
nant diffuse alveolar disease and lacks the respiratory
decompensation associated with the clinical syndrome
of acute respiratory distress. Relative to the recently
developed NHP models [9,11], the Syrian hamster
model exhibits a similar mild disease phenotype and
is well suited for assessing therapeutics or vaccines.
Another effective small animal model of COVID-
19, the human ACE2 mouse, show these animals
develop pneumonia resulting in fatal disease following
SARS-CoV-2 infection [16,26,40]. However, with this
mouse model there is concern about the location and
level of receptor expression in these human ACE2
transgenic mice. The increase in expression locales
and levels could result in enhanced or systemic disease
dissimilar to COVID-19 in humans as these animals
have been reported to develop fatal encephalitis [40],
a clinical manifestation not currently associated with
severe COVID-19 disease in humans. Additionally,
the human ACE2 mouse has been previously shown
to cause neuronal death without evidence of encepha-
litis in the SARS-CoV-1 model [41]. These compli-
cations may limit therapeutic studies in the human
ACE2 mouse model.
Although, as with all animal models, there are some
limitations exemplified by the lack of a systemic
response to SARS-CoV-2 infection. The only mild dis-
ease manifestation and ability to quickly limit the
infection make this model less suitable to study the
mechanisms of severe COVID-19. However, the con-
sistent and easily measured lung disease found in
hamsters of all ages and sex make this a suitable infec-
tion model to evaluate SARS-CoV-2 countermeasure
development.
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